Gene Vector Technologies (GVT) is one of the very few gene therapy companies in Israel. Little gene therapy research is conducted in Israel either, and commercial applications are virtually nonexistent.
Gene therapy is different from regular drug therapies in that it works by inserting a complete gene into the body, rather than by altering a gene’s function. Gene therapy tries to insert a healthy gene into a cell that lacks it, or is dysfunctional. Sometimes a gene is inserted in a cell where it never existed in nature.
GVT CEO Ehud Yosha says, “The principle is to insert the gene into the cell nucleus to instruct the production of the protein we want to be expressed in that cell.” Current gene therapy research is focusing on treating certain types of cancers and hereditary diseases, including hemophilia, thalassemia and liver diseases.
Why “trying”? Because gene therapy has encountered several serious problems that are delaying its widespread use. Yosha explains that the greatest hurdle is selecting a suitable vector, the corpuscle on which the gene will ride into the body. No completely suitable vehicle has yet been found. “Vectors used until now have had two main hurdles. One is the efficacy of the insertion. The gene cannot always be inserted into the body in a way that allows it to function long enough to effect a cure.”
The second hurdle is safety. This is a major issue. The death of a patient in September 1999 from a gene therapy delayed and deterred clinical trials. The deceased, Jesse Gelsinger, 18, was participating in a clinical trial at the Institute for Human Gene Therapy at the University of Pennsylvania to treat a rare liver disease. In that case, the vehicle used to insert the gene was an adenovirus.
Yosha explains, “The body’s immune system aggressively fights the adenovirus vector. That was not anticipated. Gelsinger died from immune rejection.”
He adds, “There are other problems of safety and toxicity, because all viral vectors are created by cell cultures. Under these circumstances, researchers have no control over events. Various genetic changes can occur in the vector, and you don’t precisely know what you’re injecting into the patient. That is the fundamental problem with all viral vectors.
“There are also liposome-based vectors (liposomes are the fatty structures that sheath DNA), or direct micro-injection of DNA into the cell. While safe to use, these methods are frequently insufficiently effective, because the body breaks down micro-injected DNA.”
So much for the problems of gene therapy vehicle maintenance. GVT is offering a solution. GVT is developing a technology utilizing the viral vector SV-40 and its preparation in a test tube from controlled composites, yielding a pseudo-virus for use as a vector for gene therapy. The procedure that is carried out in the test tube is more efficient and controlled than if it were carried out in a cell culture.
Yosha says, “We are developing a simple protein that contains only the gene we wish to insert. There is no viral DNA or genetic changes in the viruses, because there is simply no viral DNA. The vector is very effective for a great number of target cells, including those for which most vectors are ineffective, such as hemoglobin inside bone marrow. The vector can also be inserted into liver, muscle and nerve cells.”
Yosha adds that safety levels are high. Production is carried out entirely in test tubes, which allows for controlled manufacturing. “No other company in the world uses this production method with such a high degree of safety and efficiency.”
If successful, the platform could be used to treat several diseases. At the moment, for efficiency’s sake, GVT is focusing on oncology, specifically solid tumor-type cancers amenable to gene therapy, such as breast cancer. Non-solid tumor cancers such as leukemia and lymphoma are not candidates for these treatments.
How does gene therapy work against cancer? Let us begin with the problem: Cancer patients treated with chemotherapy suffer from a severe fall in their white blood cell count, damaging the immune system, and resulting in even more fragile and susceptible health.
GVT utilizes the MDR-1 gene, because it encodes a P-glycoprotein (P-gp), a cell transmembrane pump that is responsible for drug efflux and resistance. Gene therapy in this case inserts the gene into the white blood cell to induce them to produce P-gp in their membranes, thereby enhancing the body’s immune system.
Yosha says, “This allows patients to absorb heavier doses of chemotherapy, without risking their lives.”
GVT is now working on this treatment, and hopes to develop other applications later, including treatments for diseases of the liver, cardiovascular and central nervous systems.
GVY was founded by Prof. Ariella Oppenheim of the Hadassah Medical Organization and Prof. Amos Oppenheim of the Hebrew University and Hadassah Hospital, Ein Kerem, Jerusalem. They began their exit from academe six years ago, when they registered their first patent. GVT began operating independently only a year ago, however. The company’s labs are based at Hadassah Hospital. The company has six employees based at the Ashkelon Technology Incubator. Other work is conducted in Jerusalem. Yosha previously worked a private bio-agricultural company before transferring to communications, business development and marketing.
After a standard investment by the Office of the Chief Scientist, GVT is now seeking financial capital. The company needs $1 million to develop and consolidate its technology.
Yosha says, “Negotiations are underway with private groups. We may very well approach venture capital funds in the near future. It is not a matter of principle. We were simply approached by some private concerns, and thought to exploit this channel as much as possible, and approach venture capital funds afterwards. Later, we’ll want to approach an pharmaceutical or biotechnology company that would be interested in the technology, but not at this stage. It is too early now, both in terms of the technology and finances. We want to approach companies when we have a higher valuation.”
“Globes”: What next?
Yosha: “We still have a two more years and some at the incubator. Then we’ll see, based on developments. It’s too soon to decide now. We are now establishing a science board that will evaluate strategic directions, and will be in contact with biotechnology companies for the purpose of research cooperation. The aim is that will ripen into business cooperation at some point.”
Yosha will be manning GVT’s booth at the Israel Bio-Tech 2002 Conference in Tel Aviv next week, where he hopes to catch the eye of potential partners and investors.
Published by Israel's Business Arena on 19 March 2002